FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361283439> ?p ?o ?g. }

• W4361283439 endingPage "2027" @default.
• W4361283439 startingPage "2027" @default.
• W4361283439 abstract "Prostate Specific Membrane Antigen-Positron Emission Tomography (PSMA-PET) is used to select recurrent prostate cancer (PCa) patients for metastases-directed therapy (MDT). We aimed to evaluate the oncologic outcomes of second-line PSMA-guided MDT in oligo-recurrent PCa patients.we performed a retrospective analysis of 113 recurrent PCa after previous radical prostatectomy and salvage therapies with oligorecurrent disease at PSMA-PET (≤3 lesions in N1/M1a-b) in three high-volume European centres. Patients underwent second-line salvage treatments: MDT targeted to PSMA (including surgery and/or radiotherapy), and the conventional approach (observation or Androgen Deprivation Therapy [ADT]). Patients were stratified according to treatments (MDT vs. conventional approach). Patients who underwent MDT were stratified according to stage in PSMA-PET (N1 vs. M1a-b). The primary outcome of the study was Progression-free survival (PFS). Secondary outcomes were Metastases-free survival (MFS) and Castration Resistant PCa free survival (CRPC-FS). Kaplan-Meier analyses assessed PFS, MFS and CRPC-FS. Multivariable Cox regression models identified predictors of progression and metastatic disease.Overall, 91 (80%) and 22 (20%) patients were treated with MDT and the conventional approach, respectively. The median follow-up after PSMA-PET was 31 months. Patients who underwent MDT had a similar PFS compared to the conventional approach (p = 0.3). Individuals referred to MDT had significantly higher MFS and CRPC-FS compared to those who were treated with the conventional approach (73.5% and 94.7% vs. 30.5% and 79.5%; all p ≤ 0.001). In patients undergoing MDT, no significant differences were found for PFS and MFS according to N1 vs. M1a-b disease, while CRPC-FS estimates were significantly higher in patients with N1 vs. M1a-b (100% vs. 86.1%; p = 0.02). At multivariable analyses, age (HR = 0.96) and ADT during second line salvage treatment (HR = 0.5) were independent predictors of PFS; MDT (HR 0.27) was the only independent predictor of MFS (all p ≤ 0.04) Conclusion: Patients who underwent second-line PSMA-guided MDT experienced higher MFS and CRPC-FS compared to men who received conventional management." @default.
• W4361283439 created "2023-03-31" @default.
• W4361283439 creator A5002188759 @default.
• W4361283439 creator A5005133362 @default.
• W4361283439 creator A5005232053 @default.
• W4361283439 creator A5007976090 @default.
• W4361283439 creator A5011155325 @default.
• W4361283439 creator A5013888713 @default.
• W4361283439 creator A5017414279 @default.
• W4361283439 creator A5019549204 @default.
• W4361283439 creator A5022182189 @default.
• W4361283439 creator A5023266580 @default.
• W4361283439 creator A5024140252 @default.
• W4361283439 creator A5025169478 @default.
• W4361283439 creator A5029088271 @default.
• W4361283439 creator A5031550729 @default.
• W4361283439 creator A5038579623 @default.
• W4361283439 creator A5060396380 @default.
• W4361283439 creator A5061623935 @default.
• W4361283439 creator A5080019020 @default.
• W4361283439 creator A5083426889 @default.
• W4361283439 creator A5084290670 @default.
• W4361283439 creator A5086087400 @default.
• W4361283439 date "2023-03-29" @default.
• W4361283439 modified "2023-10-18" @default.
• W4361283439 title "PSMA-PET Guided Treatment in Prostate Cancer Patients with Oligorecurrent Progression after Previous Salvage Treatment" @default.
• W4361283439 cites W2050146329 @default.
• W4361283439 cites W2103623995 @default.
• W4361283439 cites W2150865892 @default.
• W4361283439 cites W2470255787 @default.
• W4361283439 cites W2591849683 @default.
• W4361283439 cites W2617065467 @default.
• W4361283439 cites W2767249739 @default.
• W4361283439 cites W2774325924 @default.
• W4361283439 cites W2775321189 @default.
• W4361283439 cites W2785084154 @default.
• W4361283439 cites W2808437932 @default.
• W4361283439 cites W2913023403 @default.
• W4361283439 cites W2945553324 @default.
• W4361283439 cites W2966792020 @default.
• W4361283439 cites W2971975450 @default.
• W4361283439 cites W3004401406 @default.
• W4361283439 cites W3013251573 @default.
• W4361283439 cites W3021097510 @default.
• W4361283439 cites W3024645857 @default.
• W4361283439 cites W3038750967 @default.
• W4361283439 cites W3116647001 @default.
• W4361283439 cites W3133949928 @default.
• W4361283439 cites W4200142001 @default.
• W4361283439 cites W4214705499 @default.
• W4361283439 cites W4220782059 @default.
• W4361283439 cites W4229056118 @default.
• W4361283439 cites W4285719527 @default.
• W4361283439 cites W4304208488 @default.
• W4361283439 cites W4313472236 @default.
• W4361283439 cites W4319443029 @default.
• W4361283439 cites W4324066800 @default.
• W4361283439 doi "https://doi.org/10.3390/cancers15072027" @default.
• W4361283439 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37046687" @default.
• W4361283439 hasPublicationYear "2023" @default.
• W4361283439 type Work @default.
• W4361283439 citedByCount "1" @default.
• W4361283439 countsByYear W43612834392023 @default.
• W4361283439 crossrefType "journal-article" @default.
• W4361283439 hasAuthorship W4361283439A5002188759 @default.
• W4361283439 hasAuthorship W4361283439A5005133362 @default.
• W4361283439 hasAuthorship W4361283439A5005232053 @default.
• W4361283439 hasAuthorship W4361283439A5007976090 @default.
• W4361283439 hasAuthorship W4361283439A5011155325 @default.
• W4361283439 hasAuthorship W4361283439A5013888713 @default.
• W4361283439 hasAuthorship W4361283439A5017414279 @default.
• W4361283439 hasAuthorship W4361283439A5019549204 @default.
• W4361283439 hasAuthorship W4361283439A5022182189 @default.
• W4361283439 hasAuthorship W4361283439A5023266580 @default.
• W4361283439 hasAuthorship W4361283439A5024140252 @default.
• W4361283439 hasAuthorship W4361283439A5025169478 @default.
• W4361283439 hasAuthorship W4361283439A5029088271 @default.
• W4361283439 hasAuthorship W4361283439A5031550729 @default.
• W4361283439 hasAuthorship W4361283439A5038579623 @default.
• W4361283439 hasAuthorship W4361283439A5060396380 @default.
• W4361283439 hasAuthorship W4361283439A5061623935 @default.
• W4361283439 hasAuthorship W4361283439A5080019020 @default.
• W4361283439 hasAuthorship W4361283439A5083426889 @default.
• W4361283439 hasAuthorship W4361283439A5084290670 @default.
• W4361283439 hasAuthorship W4361283439A5086087400 @default.
• W4361283439 hasBestOaLocation W43612834391 @default.
• W4361283439 hasConcept C121608353 @default.
• W4361283439 hasConcept C126322002 @default.
• W4361283439 hasConcept C126838900 @default.
• W4361283439 hasConcept C143998085 @default.
• W4361283439 hasConcept C146357865 @default.
• W4361283439 hasConcept C151730666 @default.
• W4361283439 hasConcept C167135981 @default.
• W4361283439 hasConcept C20417620 @default.
• W4361283439 hasConcept C2775842073 @default.
• W4361283439 hasConcept C2776694085 @default.
• W4361283439 hasConcept C2777008409 @default.
• W4361283439 hasConcept C2777899217 @default.

• next